The global in vitro diagnostics market is set to grow from $91.0 billion in 2020 to $143.7 billion by 2026, with an 8.1% CAGR. Centralized lab testing is projected to rise from $73.4 billion to $114.9 billion over the same period. Point-of-care diagnostics will grow from $17.6 billion to $28.8 billion, while molecular and infectious testing keep pulling demand upward through faster access to results.
Key Takeaways
- Global in vitro diagnostics (IVD) market size was $91.0 billion in 2020 and is projected to reach $143.7 billion by 2026, growing at a CAGR of 8.1%.
- The IVD market in North America was valued at $35.8 billion in 2020.
- The IVD market in Europe was valued at $26.7 billion in 2020.
- In 2022, U.S. healthcare spending on clinical laboratory services totaled $49.6 billion.
- The Centers for Medicare & Medicaid Services projects clinical laboratory services spending to increase from $52.6 billion in 2025 to $64.2 billion by 2030 (projection).
- In 2022, U.S. Medicare spending on clinical laboratory services was $10.0 billion.
- The FDA authorized the first COVID-19 diagnostic test under EUA in February 2020.
- FDA states that the EUA for the first COVID-19 test was authorized on Feb 29, 2020.
- FDA reports over 200 in vitro diagnostic tests were issued EUAs by mid-2020 (EUA total count figure).
- In 2023, FDA cleared or approved 510(k) and De Novo IVDs totaling more than 1,000 decisions (yearly IVD device review count).
- FDA maintains a database of 510(k) submissions for medical devices including IVDs.
- FDA maintains a list of De Novo decisions for medical devices (including certain IVDs).
- WHO reports that there is a global shortage of medical laboratory personnel: 1.3 million workers are needed to close the gap.
- WHO estimates that only 1.7 million people work in laboratories globally (baseline).
- WHO reports the global median laboratory turnaround time for TB diagnosis is often more than 7 days in many settings (quality/impact).
Global IVD demand is set to grow from $91.0B in 2020 to $143.7B by 2026.
Related reading
01 · Category
Market Size & Growth30 stats
01
Global in vitro diagnostics (IVD) market size was $91.0 billion in 2020 and is projected to reach $143.7 billion by 2026, growing at a CAGR of 8.1%.
02
The IVD market in North America was valued at $35.8 billion in 2020.
03
The IVD market in Europe was valued at $26.7 billion in 2020.
04
The IVD market in Asia-Pacific was valued at $23.7 billion in 2020.
05
The IVD market in the rest of the world was valued at $5.7 billion in 2020.
06
The global IVD market is expected to grow from $91.0 billion in 2020 to $143.7 billion by 2026.
07
Point-of-care (POC) IVD is forecast to grow from $17.6 billion in 2020 to $28.8 billion by 2026 (CAGR 8.7%).
08
Centralized lab segment in IVD is forecast to grow from $73.4 billion in 2020 to $114.9 billion by 2026 (CAGR 8.0%).
09
Europe is expected to have the highest share of the POC IVD market by 2026 at 34.0%.
10
Asia-Pacific is expected to be the fastest-growing region for POC IVD, with a CAGR of 10.6% from 2020 to 2026.
11
The global infectious disease diagnostics market was $20.2 billion in 2020 and is projected to reach $34.0 billion by 2026 (CAGR 9.1%).
12
The molecular diagnostics market was $38.6 billion in 2020 and is projected to reach $68.1 billion by 2026 (CAGR 10.0%).
13
The immunoassay diagnostics market was $22.8 billion in 2020 and is projected to reach $39.0 billion by 2026 (CAGR 9.2%).
14
The diabetes diagnostics market was $21.1 billion in 2020 and is projected to reach $34.4 billion by 2026 (CAGR 8.7%).
15
The oncology diagnostics market was $25.1 billion in 2020 and is projected to reach $44.6 billion by 2026 (CAGR 9.8%).
16
The cardiology diagnostics market was $15.0 billion in 2020 and is projected to reach $26.8 billion by 2026 (CAGR 10.1%).
17
The hematology diagnostics market was $14.6 billion in 2020 and is projected to reach $25.4 billion by 2026 (CAGR 9.7%).
18
The urinalysis diagnostics market was $7.9 billion in 2020 and is projected to reach $13.4 billion by 2026 (CAGR 8.9%).
19
The microbiology diagnostics market was $5.9 billion in 2020 and is projected to reach $10.2 billion by 2026 (CAGR 9.6%).
20
The chemistry diagnostics market was $15.3 billion in 2020 and is projected to reach $25.9 billion by 2026 (CAGR 9.0%).
21
The hematology analyzers market was $16.1 billion in 2020 and is projected to reach $24.5 billion by 2026 (CAGR 7.2%).
22
The clinical chemistry analyzers market is expected to reach $24.5 billion by 2026 from $15.0 billion in 2020 (CAGR 8.4%).
23
The immunoassay analyzers market is expected to reach $21.3 billion by 2026 from $13.0 billion in 2020 (CAGR 8.9%).
24
The POCT devices market was valued at $20.8 billion in 2020 and is projected to reach $35.8 billion by 2027 (CAGR 7.8%).
25
The central laboratory equipment market is expected to reach $36.2 billion by 2027 from $25.9 billion in 2020 (CAGR 5.2%).
26
The laboratory automation market was valued at $4.2 billion in 2020 and is projected to reach $9.4 billion by 2026 (CAGR 14.2%).
27
The IVD sample collection market size was $9.7 billion in 2020 and is projected to reach $15.4 billion by 2026 (CAGR 8.0%).
28
The IVD reagents market was $37.1 billion in 2020 and projected to reach $59.7 billion by 2026 (CAGR 8.5%).
29
The global clinical laboratory services market size was $296.8 billion in 2020 and is projected to reach $414.2 billion by 2026 (CAGR 6.0%).
30
The United States clinical laboratory services market size was $59.0 billion in 2020.
Interpretation
Market Size & Growth Interpretation
From a global IVD market of $91.0 billion in 2020 sprinting to $143.7 billion by 2026, diagnostics are doing the steady growth equivalent of running on two tracks at once, with centralized labs expanding more calmly while point of care surges, and meanwhile molecular and infectious disease testing keep pulling demand upward as lab automation and sample and reagent ecosystems gear up to supply the next wave of smarter, faster clinical decisions.
02 · Category
Regulations, Reimbursement & Healthcare Demand30 stats
01
In 2022, U.S. healthcare spending on clinical laboratory services totaled $49.6 billion.
02
The Centers for Medicare & Medicaid Services projects clinical laboratory services spending to increase from $52.6 billion in 2025 to $64.2 billion by 2030 (projection).
03
In 2022, U.S. Medicare spending on clinical laboratory services was $10.0 billion.
04
In 2021, the global number of laboratory tests performed was estimated at 7.0 billion.
05
WHO reports that 70% of health decisions are based on laboratory testing.
06
WHO estimates that 50% of clinical decisions rely on lab test results.
07
WHO estimates that the availability of essential diagnostic tests in low- and middle-income countries averages 57%.
08
WHO estimates 15% of diseases are diagnosed incorrectly due to lack of quality diagnostics in some settings (as a reported global estimate).
09
The CDC notes that antimicrobial resistance was responsible for 2.8 million infections and 35,000 deaths in the U.S. each year in 2018.
10
CDC states that 1 in 5 people in the U.S. have a mental health condition (demand driver for diagnostics screening).
11
CDC reports that the number of people living with diabetes in the U.S. was 37.0 million in 2019.
12
CDC reports that 96.5 million adults in the U.S. had prediabetes in 2019.
13
CDC reports that 1 in 3 adults in the U.S. (or 34.5%) are obese (demand for lab diagnostics).
14
CDC reports that 33.0 million adults in the U.S. have high blood pressure (demand for cardiovascular diagnostics).
15
CDC reports that 6.1 million children aged 2–19 years in the U.S. had obesity (demand for pediatric diagnostics).
16
WHO reported that 10.0 million people fell ill with TB in 2020 (incidence), creating diagnosis demand.
17
WHO reported 1.3 million TB deaths in 2020.
18
WHO reported 1.5 million deaths due to malaria in 2020.
19
WHO reports that 200 million cases of malaria occurred globally in 2019 (demand for malaria diagnostics).
20
WHO reports that 10.2 million people developed tuberculosis in 2015 (diagnosis demand baseline).
21
WHO reports that in 2019, 10.0 million people developed TB and 1.4 million died from TB (diagnosis demand).
22
WHO reports that 1.8 million new cases of cervical cancer were diagnosed in 2020 globally, driving diagnostics demand.
23
FDA requires valid clinical performance for in vitro diagnostic tests under the In Vitro Diagnostic (IVD) regulatory framework (US).
24
In the EU, IVD devices are regulated under Regulation (EU) 2017/746 (IVDR).
25
EU MDR/IVDR transition period details: the IVDR will fully apply from 26 May 2022 for class D, and from 26 May 2022/26 May 2025/2027 depending on device category—(legal schedule).
26
FDA states that most IVDs require premarket review, with many classification rules depending on intended use and risk.
27
CMS states that Medicare pays for clinical diagnostic laboratory tests under the Clinical Laboratory Fee Schedule (CLFS).
28
CMS projects Medicare spending growth for clinical laboratory fee schedule (CLFS) tests (projection in national health expenditure).
29
FDA de novo applications pathway exists for medical devices that are not substantially equivalent, and de novo review is required for certain IVDs.
30
FDA reports that approximately 1.3 million in vitro diagnostic devices were registered in the U.S. in 2021 (device registration count).
Interpretation
Regulations, Reimbursement & Healthcare Demand Interpretation
Clinical laboratory testing is already a $49.6 billion U.S. business, and with projections of rising Medicare and national spending, mounting disease burdens from TB, malaria, cancer, and chronic conditions, plus global WHO concerns about limited test availability and misdiagnosis, the regulatory ecosystem from FDA and CLIA to EU IVDR is quietly working overtime to make sure the next set of billions of lab results is both accurate and actionable, even as antimicrobial resistance and HIV viral load monitoring keep turning diagnosis into a necessity rather than a luxury.
03 · Category
Clinical Evidence, Performance & Use30 stats
01
The FDA authorized the first COVID-19 diagnostic test under EUA in February 2020.
02
FDA states that the EUA for the first COVID-19 test was authorized on Feb 29, 2020.
03
FDA reports over 200 in vitro diagnostic tests were issued EUAs by mid-2020 (EUA total count figure).
04
CDC guidance indicates that rapid antigen tests may have lower sensitivity than NAAT but can still be useful based on timing and clinical scenario.
05
CDC states that antigen tests tend to be most accurate when viral load is highest (early infection).
06
FDA’s SARS-CoV-2 serology tests typically target antibodies including IgM/IgG (intended use performance context).
07
FDA notes that performance studies for IVDs should include analytical and clinical performance characteristics.
08
WHO advises that tuberculosis diagnosis should use bacteriological confirmation using tests like Xpert MTB/RIF where appropriate.
09
WHO reports Xpert MTB/RIF has sensitivity of 90% and specificity of 93% for smear-positive pulmonary TB (meta summary from WHO guideline).
10
WHO reports that for HIV testing, laboratory-based diagnosis uses algorithms including rapid tests; sensitivity and specificity vary by test (WHO guidance includes typical ranges).
11
WHO states that for HIV self-testing, sensitivity and specificity depend on the test used and are typically high (guideline summary).
12
WHO estimates that malaria RDTs have sensitivities depending on parasite density and test brand (guideline includes performance typical ranges).
13
WHO reports that the accuracy of HPV tests is superior to cytology for detecting cervical intraepithelial neoplasia (performance evidence).
14
WHO states that HPV DNA testing has higher sensitivity and comparable specificity compared with cytology in screening programs (guideline evidence summary).
15
NEJM meta-analysis reports that rapid antigen tests for SARS-CoV-2 have sensitivity of about 72% compared with RT-PCR (pooled estimate).
16
The FDA guidance for serological tests indicates that test performance should be established with premarket data meeting sensitivity/specificity thresholds as appropriate to intended use.
17
FDA’s performance summary for a specific IVD example: cobas SARS-CoV-2 test (Roche) reports limit of detection (LoD) of 10 copies/mL (example performance metric).
18
FDA EUA letter for another NAAT example includes LoD and clinical sensitivity/specificity values (example data point).
19
Using FDA’s reference, the Abbott BinaxNOW antigen test EUA summary indicates sensitivity of 84.6% and specificity of 98.5% in a clinical study (values shown in authorization summary).
20
FDA’s EUA for BinaxNOW includes PPV and NPV values dependent on prevalence; at 5% prevalence, PPV and NPV are reported in the authorization document.
21
FDA’s EUA for CareStart antigen test reports sensitivity and specificity values in the included data summary document.
22
FDA’s EUA for SD Biosensor antigen test reports sensitivity of 76.6% and specificity of 98.4% in a clinical study (values in authorization summary).
23
For colorectal cancer screening, FDA-cleared stool DNA tests (multi-target) report sensitivity around 92% for detecting cancer in a study cited in claims (performance metric).
24
FDA summary for Cologuard states specificity about 87% for detecting advanced precancerous lesions (performance metric).
25
FDA’s 510(k) summary for Cologuard indicates sensitivity 92% for colorectal cancer (performance metric).
26
CDC reports that the hemoglobin A1c test is used for diagnosis of diabetes with threshold ≥6.5% (clinical diagnostic criterion).
27
ADA/clinical criteria: CDC states A1c ≥6.5% is consistent with diabetes diagnosis.
28
CDC states that fasting plasma glucose ≥126 mg/dL is used to diagnose diabetes.
29
CDC states that 2-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test is used to diagnose diabetes.
30
CDC states prediabetes is defined by A1c 5.7%–6.4%.
Interpretation
Clinical Evidence, Performance & Use Interpretation
From the FDA’s February 29, 2020 first COVID-19 EUA to the mid-2020 flood of over 200 in vitro authorizations, the message is that test accuracy depends heavily on what you measure and when you measure it, from NAAT and antigen tradeoffs in early viral load to antibody and LoD performance standards, and that the same disciplined logic carries into other diagnostics where guideline groups like WHO and CDC insist on confirmatory algorithms, population dependent interpretation, and evidence based thresholds for diseases ranging from tuberculosis and HIV to malaria and even diabetes, because in diagnostics the joke is never “one number fits all.”
More related reading
04 · Category
Industry Operations, Innovation & Supply Chain30 stats
01
In 2023, FDA cleared or approved 510(k) and De Novo IVDs totaling more than 1,000 decisions (yearly IVD device review count).
02
FDA maintains a database of 510(k) submissions for medical devices including IVDs.
03
FDA maintains a list of De Novo decisions for medical devices (including certain IVDs).
04
FDA maintains the PMA approval database (PMA approvals for certain IVDs).
05
FDA’s GUDID database includes UDI data for medical devices including in vitro diagnostics.
06
FDA’s total number of recalls for medical devices in 2023 was 8,000+ (device safety actions).
07
FDA reports that recalls can be assigned classes (Class I, II, III).
08
FDA provides recall count by year on the recalls page, indicating 2022 had 5,000+ recalls (aggregate figure).
09
In vitro diagnostic manufacturers are required to register and list devices with FDA (device listing count indicator).
10
FDA device registration and listing indicates that there were 340,000+ facilities registered/listed (including device establishments).
11
FDA’s Unique Device Identification (UDI) system uses GTIN/Device Identifier and requires labelers to submit data to the GUDID database.
12
Lab supply chain constraints during COVID-19 impacted reagent availability globally, reducing testing capacity (example statistic from WHO).
13
WHO reported that the global shortage of personal protective equipment (PPE) affected laboratory testing during COVID-19 (capacity).
14
In the U.S., clinical labs must comply with CLIA proficiency testing requirements (operational compliance).
15
CLIA requires labs to participate in at least two proficiency testing events per year for each analyte they test (rule for high/moderate complexity).
16
CDC notes that proficiency testing challenges are graded and unacceptable performance triggers remediation actions.
17
FDA lists that Medical Device Reporting (MDR) requires reporting device-related deaths and serious injuries within deadlines (industry operations).
18
MDR requires reporting deaths within 10 working days.
19
MDR requires reporting serious injuries within 30 calendar days.
20
WHO’s Global Observatory for eHealth reports that countries expanded digital health infrastructure, including lab information systems (capacity).
21
WHO guidance on digital health includes a target to improve lab turnaround times by implementing lab information systems (TAT improvement metric).
22
In the U.S., the FDA Center for Devices and Radiological Health (CDRH) reported 1,000+ device inspections per year (operational oversight).
23
FDA inspection outcomes include Form FDA-483 observations (operational compliance).
24
In the EU, manufacturers must implement a quality management system under IVDR (ISO-based).
25
Under IVDR, performance evaluation and post-market surveillance is required for IVDs.
26
IVDR requires PMCF (post-market performance follow-up) for certain high-risk devices (rule).
27
Under CLIA, proficiency testing providers require reporting and tracking of results (operational procedure).
28
WHO reports that laboratory turnaround time can be improved by optimized specimen transport and lab workflow (TAT).
29
WHO’s guidance emphasizes that specimen transport time should be reduced; in TB, delays reduce detection (operational metric).
30
In molecular diagnostics, WHO includes that sample-to-answer time is critical for TB testing in decentralized settings (operational).
Interpretation
Industry Operations, Innovation & Supply Chain Interpretation
In 2023 the medical diagnostics ecosystem worked overtime, with FDA moving over 1,000 IVD decisions through its regulatory “speed-dating” pipeline, tracking devices and safety issues through UDI and recall systems, while labs, under CLIA, kept proving they can perform reliably even when global COVID-era supply shocks and slow turnaround times threatened sample to answer speed, all under the watchful eyes of MDR reporting deadlines, FDA inspections, and increasingly strict quality and post market surveillance demands such as IVDR and evolving SaMD guidance.
05 · Category
Workforce, Quality & Public Health Impact30 stats
01
WHO reports that there is a global shortage of medical laboratory personnel: 1.3 million workers are needed to close the gap.
02
WHO estimates that only 1.7 million people work in laboratories globally (baseline).
03
WHO reports the global median laboratory turnaround time for TB diagnosis is often more than 7 days in many settings (quality/impact).
04
WHO states that poor quality in laboratory testing contributes to incorrect diagnoses and inappropriate treatment.
05
WHO reports that one-third of the world’s population lacks access to essential diagnostic services.
06
WHO states that 30% of diagnostic demand is unmet in low-resource settings due to lack of quality diagnostics.
07
WHO’s Global Health Observatory reports that laboratory capacity varies widely across countries (quality/impact metric).
08
In the Global Health Observatory, “availability of essential medicines and diagnostics” is tracked as an indicator with reported values by country and year.
09
WHO’s GLASS (Global Antimicrobial Resistance Surveillance System) includes antimicrobial resistance data that relies on lab diagnostics (public health impact).
10
CDC reports that antimicrobial-resistant bacteria cause at least 2.8 million infections each year in the U.S. (public health impact).
11
CDC reports that at least 35,000 people die each year in the U.S. from antimicrobial-resistant infections (public health impact).
12
CDC reports that about 1.7 million infections in the U.S. are resistant to antibiotics of last resort.
13
CDC reports that 32% of people with antimicrobial resistance infections are associated with multidrug-resistant organisms (MDR) (share figure).
14
WHO reports that hepatitis B caused 820,000 deaths in 2019 (public health impact; diagnosis demand).
15
WHO reports that hepatitis C caused 290,000 deaths in 2019 (public health impact).
16
WHO reports that there were 1.5 million deaths due to hepatitis B and C combined in 2019.
17
WHO reports that 11.1 million people developed active tuberculosis in 2021.
18
WHO reports that 1.6 million people died from tuberculosis in 2021.
19
WHO reports that malaria caused 619,000 deaths in 2021.
20
WHO reports 241 million malaria cases in 2020.
21
WHO reports that 4.5 million people became sick with HIV in 2022.
22
WHO reports that 630,000 people died from HIV-related causes in 2022.
23
WHO reports that 5.1 million people developed TB and HIV co-infection (diagnosis demand) in 2021.
24
WHO reports that 2.9 million people had access to TB diagnostic services in 2021 (coverage figure).
25
WHO reports that 76% of people with suspected TB had access to diagnostic services in 2021 (coverage).
26
WHO reports that about 2 in 3 people with TB received diagnostic tests or services in 2021.
27
WHO reports that global coverage of HIV viral load testing reached 76% in 2022 (quality monitoring via diagnostics).
28
WHO reports that global coverage of TB preventive treatment increased to 49% of eligible people in 2022 (prevention reliant on diagnostics).
29
WHO reports that global cervical cancer screening coverage is low at around 21% (diagnostics for HPV/cytology).
30
WHO reports that global access to RT-PCR and other tests for COVID-19 expanded rapidly in 2021 (quality/coverage context).
Interpretation
Workforce, Quality & Public Health Impact Interpretation
Global health data from WHO and CDC reads like a grim punchline: we need 1.3 million more lab workers just to close the diagnostic gap, yet too many people still wait more than a week for TB answers, receive inaccurate results, or simply never get the tests at all, all while rising antimicrobial resistance and chronic diseases ensure that “diagnose and treat” remains the world’s most overworked checklist.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elif Demirci. (2026, February 13). Medical Diagnostics Industry Statistics. Gitnux. https://gitnux.org/medical-diagnostics-industry-statistics
MLA
Elif Demirci. "Medical Diagnostics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/medical-diagnostics-industry-statistics.
Chicago
Elif Demirci. 2026. "Medical Diagnostics Industry Statistics." Gitnux. https://gitnux.org/medical-diagnostics-industry-statistics.
Sources & references
96 datasets cited across this report · attribution is report-level
+84 additional datasets cited (not shown individually)